tetrahydrocurcumin has been researched along with Cardiomyopathies, Primary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Duan, W; Jia, H; Jiang, L; Li, K; Li, X; Liu, J; Xia, L; Xu, L; Yu, S; Zhai, M; Zhang, L; Zhou, Y; Zhu, H | 1 |
| Duan, W; Jiang, L; Jin, Z; Li, X; Liu, J; Sun, J; Xing, S; Xu, C; Xue, C; Yang, J; Yu, S; Zhang, B; Zhang, L; Zhu, H | 1 |
2 other study(ies) available for tetrahydrocurcumin and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Tetrahydrocurcumin improves lipopolysaccharide-induced myocardial dysfunction by inhibiting oxidative stress and inflammation via JNK/ERK signaling pathway regulation.
Topics: Animals; Cardiomyopathies; Curcumin; Inflammation; Lipopolysaccharides; MAP Kinase Signaling System; Mice; Oxidative Stress; Sepsis | 2022 |
Tetrahydrocurcumin ameliorates postinfarction cardiac dysfunction and remodeling by inhibiting oxidative stress and preserving mitochondrial function via SIRT3 signaling pathway.
Topics: Animals; Apoptosis; Cardiomyopathies; Male; Mice; Mice, Inbred C57BL; Mitochondria; Myocardial Infarction; Myocytes, Cardiac; NF-E2-Related Factor 2; Oxidative Stress; Signal Transduction; Sirtuin 3 | 2023 |